The Food and Drug Administration (FDA) recently approved the nasal spray Spravato for the treatment of major depression in ...

The expanded indication allows esketamine nasal spray to be used as a standalone treatment in adults with MDD who have not ...

Spravato is now the first stand-alone therapy for treatment-resistant depression, for patients who haven’t responded to oral ...

A ketamine-based nasal spray is officially the first and only standalone therapy available for treatment-resistant depression ...

People with treatment-resistant depression can now take Spravato's ketamine-derived nasal spray as a standalone treatment.

Major depression has one of the highest economic burdens of any psychiatric disorder,” he pointed out. Now, the FDA has also approved Spravato for treating adults with MDD who have not responded ...

Inc. stock despite strong Phase 2b data. Click for my updated look at MNMD stock and its market opportunities.

The US FDA has approved the first of its kind ketamine-based nasal spray which is supposed to act as a standalone therapy for ...

Johnson & Johnson reported that Spravato treated over 100,000 patients in 77 countries worldwide, including roughly 80,000 in ...

The results, which come on the heels of the FDA’s approval of J&J’s esketamine nasal spray Spravato as a monotherapy for ...

CIII allows people who have tried at least two oral antidepressants to use the spray on its own – without the need for more ...